Jubilant Ingrevia July 2024 Q1 FY25 Investor Presentation

Jubilant Ingrevia Limited presents Q1 FY2025 financial results and business updates highlighting improved specialty chemicals performance, strong CDMO growth, and expanding pharmaceutical market penetration in North America, Europe, and Japan. The presentation discusses operational progress across pyridine derivatives, niacinamide, and acetyl segments with recovery signals in agrochemicals despite ongoing pricing pressures.